Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 4, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Brain Metastases, AdultBrain MetastasesBrain Cancer
Interventions
DRUG

18F fluciclovine

Patients will receive a standard 5 millicuries dose of 18F-fluciclovine intravenously as a bolus injection. They will be required to fast for at least four hours prior to 18F-fluciclovine injection. Patients will be positioned for PET/CT brain imaging and will be injected with 18F-fluciclovine immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.

Trial Locations (1)

33176

RECRUITING

Miami Cancer Institute, Miami

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Blue Earth Diagnostics

INDUSTRY

lead

Baptist Health South Florida

OTHER